CRF Health Announces Global Partnership with Vodafone
CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, has announced a new partnership with Vodafone. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients.
As a result of the partnership, managing mobile data sending in clinical studies using the TrialMax eCOA platform is made significantly easier and more predictable for CRF Health clients. The agreement provides clinical trial sponsors running global studies with assured connectivity and instant access to data through Vodafone’s global network. Reliability, security and integration are crucial to ensure that healthcare industry requirements and standards are met.
“Having a trusted communications services partner is critical for us," commented CRF Health’s Vice President of Contracts and Vendor Management, Jaime Racine. She continues, "Partnering with Vodafone will help us provide our clients with more predictable data sending while improving the quality of our products and services”.
Vodafone Group’s Head of Machine-to-Machine Sales for Northern Europe, Cyril Deschanel, said: “Our global M2M platform and services allow CRF Health to confidently provide customers with reliable global end-to-end solutions for clinical trials to ensure the highest quality outcomes. Working together with CRF Health, we can achieve their goal of a seamless global experience and greater operational efficiency.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.